Biocon Biologics, RSSDI collaborate to expand access to insulins for diabetic kids

As the world celebrates the 100th anniversary of the discovery of insulin, a therapy that has transformed Type 1 diabetes from a once-fatal diagnosis into a chronic, manageable condition, Biocon Biologics has expanded its universal access program to include children with Type 1 diabetes from marginalized communities in India.

Addressing the Biocon Biologics Scientific Symposium at the 49th Annual Conference of RSSDI held to commemorate World Diabetes Day on November 14, 2021, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said: "As a part of the centenary celebrations of the discovery of insulin, Biocon Biologics has expanded its universal access program to address the needs of young people with Type 1 diabetes in India in collaboration with RSSDI. With the help of ~400 physicians across the country, we aim to provide global quality, lifesaving insulins to over 1,000 children who otherwise cannot afford this therapy."

"Through our various access initiatives, Biocon Biologics is committed to enabling affordability, accessibility and availability of our insulins to the most underserved and vulnerable sections of the diabetes population in India," she added.

Dr Banshi Saboo, President and Organising Chairman, RSSDI, said: "We are delighted to associate with Biocon Biologics to improve diabetes management for better patient outcomes, especially the marginalised who cannot afford the high cost of medicines. We are glad to be able to improve the quality of life for thousands of people with diabetes."

At the symposium, Biocon Biologics presented the clinical study data submitted to the U.S. Food and Drug Administration based on which the Company received world's first interchangeability approval for its biosimilar Insulin Glargine.

"The Company has served over 1 million people with diabetes in India through its insulins portfolio, which includes Insulin Glargine and recombinant human insulin in various presentations. As a credible, global insulins player, Biocon Biologics is taking forward its mission of expanding affordable access to quality insulins for people with diabetes across the world. To commemorate 100 years of insulin discovery, Biocon Biologics is observing the Diabetes Awareness Month with a series of activities viz., HCP Engagement through its digital i-connect platform and face-to-face interactions, a Diabetes Awareness Campaign on Social Media, Diabetes Detection Camps, as well as Walkathons with participating HCPs for raising awareness on Diabetes," the release stated.

Read also: Biocon Biologics, Viatris interchangeable biosimilar Insulin Glargine preferred on Express Scripts' largest formulary in US